Porphyria cutanea tarda: Difference between revisions

Jump to navigation Jump to search
Line 17: Line 17:
==Causes==
==Causes==
*In the acquired form, the signs and symptoms of this condition are triggered by non genetic factors such as alcohol abuse, excess iron, certain hormones, and viral infections. However, in the inherited form of the disease, which affects up to 20% of PCT patients, the condition arises from a mutation in the uroporphyrinogen decarboxylase gene, although environmental and chemical factors may trigger or exacerbate symptoms.
*In the acquired form, the signs and symptoms of this condition are triggered by non genetic factors such as alcohol abuse, excess iron, certain hormones, and viral infections. However, in the inherited form of the disease, which affects up to 20% of PCT patients, the condition arises from a mutation in the uroporphyrinogen decarboxylase gene, although environmental and chemical factors may trigger or exacerbate symptoms.
*Drug side effect: [[Chlorpropamide]], [[Tolbutamide]]
*Drug side effect: [[Chlorpropamide]], [[Tolbutamide]], [[Tolazamide]]


==Diagnosis==
==Diagnosis==

Revision as of 14:59, 24 February 2015

Template:DiseaseDisorder infobox

WikiDoc Resources for Porphyria cutanea tarda

Articles

Most recent articles on Porphyria cutanea tarda

Most cited articles on Porphyria cutanea tarda

Review articles on Porphyria cutanea tarda

Articles on Porphyria cutanea tarda in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Porphyria cutanea tarda

Images of Porphyria cutanea tarda

Photos of Porphyria cutanea tarda

Podcasts & MP3s on Porphyria cutanea tarda

Videos on Porphyria cutanea tarda

Evidence Based Medicine

Cochrane Collaboration on Porphyria cutanea tarda

Bandolier on Porphyria cutanea tarda

TRIP on Porphyria cutanea tarda

Clinical Trials

Ongoing Trials on Porphyria cutanea tarda at Clinical Trials.gov

Trial results on Porphyria cutanea tarda

Clinical Trials on Porphyria cutanea tarda at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Porphyria cutanea tarda

NICE Guidance on Porphyria cutanea tarda

NHS PRODIGY Guidance

FDA on Porphyria cutanea tarda

CDC on Porphyria cutanea tarda

Books

Books on Porphyria cutanea tarda

News

Porphyria cutanea tarda in the news

Be alerted to news on Porphyria cutanea tarda

News trends on Porphyria cutanea tarda

Commentary

Blogs on Porphyria cutanea tarda

Definitions

Definitions of Porphyria cutanea tarda

Patient Resources / Community

Patient resources on Porphyria cutanea tarda

Discussion groups on Porphyria cutanea tarda

Patient Handouts on Porphyria cutanea tarda

Directions to Hospitals Treating Porphyria cutanea tarda

Risk calculators and risk factors for Porphyria cutanea tarda

Healthcare Provider Resources

Symptoms of Porphyria cutanea tarda

Causes & Risk Factors for Porphyria cutanea tarda

Diagnostic studies for Porphyria cutanea tarda

Treatment of Porphyria cutanea tarda

Continuing Medical Education (CME)

CME Programs on Porphyria cutanea tarda

International

Porphyria cutanea tarda en Espanol

Porphyria cutanea tarda en Francais

Business

Porphyria cutanea tarda in the Marketplace

Patents on Porphyria cutanea tarda

Experimental / Informatics

List of terms related to Porphyria cutanea tarda

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]


Overview

Porphyria cutanea tarda (PCT) is the most common subtype of porphyria. The disorder results from low levels of the enzyme responsible for the fifth step in heme production. Heme is a vital molecule for all of the body's organs. It is a component of hemoglobin, the molecule that carries oxygen in the blood.

Presentation

When signs and symptoms occur, they usually begin in adulthood and result from the skin becoming overly sensitive to sunlight. Areas of skin exposed to the sun develop severe blistering, scarring, changes in pigmentation, and increased hair growth. Exposed skin becomes fragile and is easily damaged. People with porphyria cutanea tarda also have increased iron levels in the liver. They face a higher risk of developing abnormal liver function and liver cancer.[1]

Causes

  • In the acquired form, the signs and symptoms of this condition are triggered by non genetic factors such as alcohol abuse, excess iron, certain hormones, and viral infections. However, in the inherited form of the disease, which affects up to 20% of PCT patients, the condition arises from a mutation in the uroporphyrinogen decarboxylase gene, although environmental and chemical factors may trigger or exacerbate symptoms.
  • Drug side effect: Chlorpropamide, Tolbutamide, Tolazamide

Diagnosis

Physical Examination

Skin

Extremities
Face

Epidemiology

This type of porphyria occurs in an estimated 1 in 25,000 people, including both inherited and sporadic (noninherited) cases. An estimated 80 % of porphyria cutanea tarda cases are sporadic. The exact frequency is not clear because many people with the condition never experience symptoms.

Genetics

Inherited mutations in the UROD gene cause about 20 % of cases (the other 80 % of cases do not have mutations in UROD, and are classified as sporadic). UROD makes an enzyme called uroporphyrinogen III decarboxylase, which is critical to the chemical process that leads to heme production. The activity of this enzyme is usually reduced by 50 % in all tissues in people with the inherited form of the condition.

Nongenetic factors such as alcohol abuse, excess iron, and others listed above can increase the demand for heme and the enzymes required to make heme. The combination of this increased demand and reduced activity of uroporphyrinogen decarboxylase disrupts heme production and allows byproducts of the process to accumulate in the body, triggering the signs and symptoms of porphyria cutanea tarda.

The HFE gene makes a protein that helps cells regulate the absorption of iron from the digestive tract and into the cells of the body. Certain mutations in the HFE gene cause hemochromatosis (an iron overload disorder). People who have these mutations are also at an increased risk of developing porphyria cutanea tarda.

In the 20% of cases where porphyria cutanea tarda is inherited, it is inherited in an autosomal dominant pattern, which means one copy of the altered gene is sufficient to decrease enzyme activity and cause the signs and symptoms of the disorder.

20% of cases of porphyria cutanea tarda are inherited in an autosomal dominant pattern.

Diagnosis

Physical Examination

Skin

Treatment

Chloroquine and venesection can be part of a management strategy.[3]

Cultural references

Porphyria Cutanea Tarda is also the name of a song by the punk band AFI on their album Black Sails in the Sunset.

References

  1. Fracanzani AL, Taioli E, Sampietro M, Fatta E, Bertelli C, Fiorelli G, Fargion S (2001). "Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease". J Hepatol. 35 (4): 498–503. PMID 11682034.
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 "Dermatology Atlas".
  3. Sarkany RP (2001). "The management of porphyria cutanea tarda". Clin Exp Dermatol. 26 (3): 225–32. PMID 11422163.

Additional Resources

  • Kauppinen R (2005). "Porphyrias". Lancet. 365 (9455): 241–52. PMID 15652607.
  • Lecha M, Herrero C, Ozalla D (2003). "Diagnosis and treatment of the hepatic porphyrias". Dermatol Ther. 16 (1): 65–72. PMID 12919129.
  • Nordmann Y, Puy H (2002). "Human hereditary hepatic porphyrias". Clin Chim Acta. 325 (1–2): 17–37. PMID 12367763.
  • Sassa S (2002). "The porphyrias". Photodermatol Photoimmunol Photomed. 18 (2): 56–67. PMID 12147038.
  • "Porphyria Cutanea Tarda" Porphyria South Africa, University of Cape Town/Groote Schurr Hospital


Template:Vesiculobullous disease Template:Endocrine, nutritional and metabolic pathology Template:SIB

de:Porphyria cutanea tarda nl:Porphyria cutanea tarda sr:Касна кожна порфирија


Template:WikiDoc Sources